(Total Views: 517)
Posted On: 10/30/2022 6:45:42 PM
Post# of 154003
NASH_14 week trial: 350 MG.
"There were NO significant differences in treatment-emergent Adverse effects between Leronlimab and Placebo groups.
"The PRIMARY endpoints (PDFF) were achieved in both intention to treat and Per Protocol populations...
"There were NO significant differences in treatment-emergent Adverse effects between Leronlimab and Placebo groups.
"The PRIMARY endpoints (PDFF) were achieved in both intention to treat and Per Protocol populations...
(2)
(0)
